Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 1/7/2020
SIETES contiene 93059 citas

 
 
 1 a 5 de 5 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Montastruc F, Sommet A, Bondon-Guitton E, Durrieu G, Bui E, Bagheri H, Lapeyre-Mestre M, Schmitt L, Montastruc J-L. The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France. Eur J Clin Pharmacol 2012;68:767-75. [Ref.ID 92823]
2. Cita con resumen
Rouve N, Bagheri H, Telmon N, Pathak A, Franchitto N, Schmitt L, Rougé D, Lapeyre-Mestre M, Montastruc J-L, The French Association of Regional PharmacoVigilance Centres. Prescribed drugs and violence: a case/noncase study in the French PharmacoVigilance Database. Eur J Clin Pharmacol 2011;67:1189-98. [Ref.ID 91779]
3. Cita con resumen
Lacroix I, Berrebi A, Garipuy D, Schmitt L, Hammou Y, Chaumerliac C, Lapeyre-Mestre M, Montastruc J-L, Damase-Michel C. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol 2011;67:1053-9. [Ref.ID 91555]
4.
Senard-Ojero A, Durrieu G, Depiesse F, Schmitt L, Riviere D, Montastruc J-L. Consommation de substances interdites chez le sportif: étude à l'Antenne Médicale de Prévention du Dopage de Midi-Pyrénées (AMPD-MP). Therapie 2010;65:459-63. [Ref.ID 89879]
5.
Lacroix L, Berrebi A, Schmitt L, Garipuy D, Lapeyre-Mestre M, Montastruc J-L. Buprenorphine high dosage in pregnancy: first data of a prospective study. Pharmacoepidemiol Drug Saf 2002;11:249. [Ref.ID 63522]
Seleccionar todas
 
 1 a 5 de 5